Kim Forest Enterprise Co., Ltd. (TPE:6645)
Taiwan
· Delayed Price · Currency is TWD 13.05
+0.05 (0.38%)
Apr 29, 2026, 1:30 PM CST
Kim Forest Enterprise Revenue
In the year 2025, Kim Forest Enterprise had annual revenue of 549.14M TWD with 9.49% growth. Kim Forest Enterprise had revenue of 176.90M in the quarter ending December 31, 2025, with 11.02% growth.
Revenue
549.14M
Revenue Growth
+9.49%
P/S Ratio
1.44
Revenue / Employee
n/a
Employees
58
Market Cap
791.14M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 549.14M | 47.62M | 9.49% |
| Dec 31, 2024 | 501.53M | 86.52M | 20.85% |
| Dec 31, 2023 | 415.01M | -255.58M | -38.11% |
| Dec 31, 2022 | 670.59M | 69.92M | 11.64% |
| Dec 31, 2021 | 600.67M | 297.78M | 98.31% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sofiva Genomics | 385.71M |
| Puriblood Medical | 117.35M |
| Genetics Generation Advancement | 603.11M |
| Pharmigene | 149.25M |
| Welgene Biotech | 375.94M |
| DIVA Laboratories | 868.84M |
| BIONET | 1.24B |